Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
On September 12, 2024, Melndale, Sweden, Sweden, Sweden, Sweden.
Nurphoto | Gets the image
Astrazeneca On Tuesday, the CEO Pascal Soriot once again confirmed the committee firm’s commitment to the US market amid reports that he was considering moving the list.
Soriot said that the company listing the UK has many reasons to be in the United States, adding that it “quickly transferred production” throughout the Atlantic so that it can serve all the needs of US patients at the domestic level.
“We have many reasons to be here (in the US),” Soriot said during a profit.
“This country (US) will represent 50% of our revenues by 2030. We have thousands of employees … across the country,” he added.
On Tuesday, Astrazeneca doubled in the US market, saying that in the second quarter of the income report on Tuesday, the country was key to its ambitions of income by the end of the decade.
“We are a world campaign, but we are definitely very, present in the US,” Soriot said, noting that he plans to become self-sufficient quickly.
The company stated that last week she planned invest 50 billion dollars Strengthening its US production capabilities and research. This notes the latest pharmaceutical firm, which increases the cost of state tariffs and calls of President Donald Trump to rethink production.
“Our investments reflect our belief in the growth of this country. We want to contribute to it,” Soriot said, noting that he met with the Trump administration to discuss growth plans in the sector.
“The United States really leads to biormoceutical innovations these days,” he added, criticizing Europe’s refusal. “Today, very little is coming out of Europe.”
Changing the state?
Astrazeneca, which has created international headlines by developing one of the COVID-19 key vaccines, has long been prioritizing the US market. In the US, in 2024, the US accounts for more than 40% of the company’s annual revenues.
Earlier this month, The Times reported that the firm could move its list from London to the US, what analysts said would be blow to the state markets of the UK.
At the time, Astrazeneca refused to comment on the report. However, Chief Financial Director Aradhan Sarin said on Tuesday that the company remains “devoted” in the UK
This happens when Astrazeneca posted more than expected on Tuesday, the profit in the second quarter, due to the demand for key cancer and bioformoceus.
During the three -month period until June 30 until June 30 until June 30 to 30 to 30, on June 30, an analyst in LSEG survey in LSEG poll in LSEG survey.
Quarterly adjusted the main profit of $ 4.58 billion against $ 4.48 billion.
FTSE 100 maintained its forecast for the full year to increase the revenue by a high unequivocal percentage and a major stock profit to increase at a low double -digit percentage.
This happens when the European Pharmaceutical Sector collies Expected fees in 15% About imports in the US as part of a broader EU-WSH trading transaction. Analysts have warned that tariffs, if accounted for 15% and above, could interfere with European firms and the wide economy of the block.
In April, Astrazenca proposed to maintain its sales recommendations in 2025, when American tariffs for European pharmaceutical products were in line with those levied against other sectors.
“This tariff issue is not really a problem that has a great effect on us,” Soriot said.
